Mutagenicity, carcinogenicity and teratogenicity of lithium compounds.
This paper reviews the information available concerning the mutagenic, teratogenic and carcinogenic effects of lithium. Such effects would be highly unlikely in an occupational setting but might be a risk to the considerable percentage of the population treated for manic-depressive disorders. It is concluded that lithium compounds have no significant clastogenic and, based on studies on microorganisms, only a doubtful mutagenic activity. Information on teratogenic effects is contradictory. While some observations in man and a few animal studies suggest that lithium in concentrations in the order of those given to patients may cause malformations, other observations do not support this claim and the risk with a carefully controlled therapy is probably small. Until more information becomes available from ongoing lithium data registries, it is probably prudent to exercise caution in treating pregnant women with lithium during the period of cardiac organogenesis. No information is available on cancer caused by treatment with lithium, and it is highly unlikely that lithium is carcinogenic.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000818:Animals; D015197:Carcinogenicity Tests; D005260:Female; D006801:Humans; D018020:Lithium Compounds / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity*; D009152:Mutagenicity Tests; D011247:Pregnancy
D018020:Lithium Compounds